

## References

### L-5015

1. Szulc P, Naylor K, Hoyle NR, et al. Use of CTX-I and PINP as bone turnover markers: National Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability. *Osteoporos Int.* Jun 19 2017. PMID 28631236
2. Johansson H, Oden A, Kanis JA, et al. A meta-analysis of reference markers of bone turnover for prediction of fracture. *Calcif Tissue Int.* May 2014;94(5):560-567. PMID 24590144
3. Biver E, Chopin F, Coiffier G, et al. Bone turnover markers for osteoporotic status assessment? A systematic review of their diagnosis value at baseline in osteoporosis. *Joint Bone Spine.* Jan 2012;79(1):20-25. PMID 21724445
4. Tamaki J, Iki M, Kadowaki E, et al. Biochemical markers for bone turnover predict risk of vertebral fractures in postmenopausal women over 10 years: the Japanese Population-based Osteoporosis (JPOS) Cohort Study. *Osteoporos Int.* Mar 2013;24(3):887-897. PMID 22885773
5. Bauer DC, Garnero P, Harrison SL, et al. Biochemical markers of bone turnover, hip bone loss, and fracture in older men: the MrOS study. *J Bone Miner Res.* Dec 2009;24(12):2032-2038. PMID 19453262
6. Zhang T, Liu P, Zhang Y et al. Combining information from multiple bone turnover markers as diagnostic indices for osteoporosis using support vector machines.. *Biomarkers*, 2018 Nov 18;24(2). PMID 30442069
7. Gutierrez-Buey G, Restituto P, Botella S et al. Trabecular bone score and bone remodelling markers identify perimenopausal women at high risk of bone loss.. *Clin. Endocrinol. (Oxf)*, 2019 May 30;91(3). PMID 31141196
8. Shieh A, Greendale GA, Cauley JA et al. Urinary N-Telopeptide as Predictor of Onset of Menopause-Related Bone Loss in Pre- and Perimenopausal Women.. *JBMR Plus*, 2019 May 3;3(4). PMID 31044185
9. Bauer DC, Garnero P, Hochberg MC, et al. Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial. *J Bone Miner Res.* Feb 2006;21(2):292-299. PMID 16418785
10. Baxter I, Rogers A, Eastell R, et al. Evaluation of urinary N-telopeptide of type I collagen measurements in the management of osteoporosis in clinical practice. *Osteoporos Int.* Mar 2013;24(3):941-947. PMID 22872068
11. Burch J, Rice S, Yang H, et al. Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups. *Health Technol Assess.* Feb 2014;18(11):1-180. PMID 24534414

12. Roux C, Giraudeau B, Rouanet S, et al. Monitoring of bone turnover markers does not improve persistence with ibandronate treatment. *Joint Bone Spine*. Jul 2012;79(4):389-392. PMID 21703900
13. Al Nofal AA, Altayar O, BenKhadra K, et al. Bone turnover markers in Paget's disease of the bone: a systematic review and meta-analysis. *Osteoporos Int*. Jul 2015;26(7):1875-1891. PMID 26037791
14. Rianon N, Alex G, Callender G, et al. Preoperative serum osteocalcin may predict postoperative elevated parathyroid hormone in patients with primary hyperparathyroidism. *World J Surg*. Jun 2012;36(6):1320-1326. PMID 22278606
15. Eastell R, Rosen CJ, Black DM et al. Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society\* Clinical Practice Guideline.. *J. Clin. Endocrinol. Metab.*, 2019 Mar 26;104(5). PMID 30907953
16. Camacho PM, Petak SM, Binkley N et al. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS - 2016--EXECUTIVE SUMMARY.. *Endocr Pract*, 2016 Sep 20;22(9). PMID 27643923
17. Cosman F, de Beur SJ, LeBoff MS, et al. Clinician's guide to prevention and treatment of osteoporosis. *Osteoporos Int*. Oct 2014;25(10):2359-2381. PMID 25182228
18. North American Menopause Society. Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society. *Menopause*. Jan-Feb 2010;17(1):25-54; quiz 55-26. PMID 20061894
19. Vasikaran S, Cooper C, Eastell R, et al. International Osteoporosis Foundation and International Federation of Clinical Chemistry and Laboratory Medicine position on bone marker standards in osteoporosis. *Clin Chem Lab Med*. Aug 2011;49(8):1271-1274. PMID 21605012
20. McCloskey EV, Vasikaran S, Cooper C. Official Positions for FRAX(R) clinical regarding biochemical markers from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX(R). *J Clin Densitom*. Jul-Sep 2011;14(3):220-222. PMID 21810528
21. U.S. Preventive Services Task Force (USPSTF). Osteoporosis to Prevent Fractures: Screening. June 2018  
<https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/osteoporosis-screening1> Accessed November 17, 2019.

22. Centers for Medicare & Medicaid Services. National Coverage Determination (NCD) for Collagen Crosslinks, any Method (190.19). 2002; <https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=96&ncdver=1&DocID=190.19&SearchType=Advanced&bc=IAAAABAAAA&>. Accessed November 17, 2019.
23. Rules and Regulations: Medicare National Coverage Decision for Collagen Crosslinks, Any Method Other Names/Abbreviations. Federal Register. 2001;66(226):58843-58844.